{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:30:38Z","timestamp":1790501438921,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":1802,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL126810"],"award-info":[{"award-number":["HL126810"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MACC Fund Center for Cancer and Blood Disorders"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1002\/rth2.12064","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T08:23:33Z","timestamp":1513067013000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Current issues in diagnosis and treatment of von Willebrand disease"],"prefix":"10.1016","volume":"2","author":[{"given":"Daniel A.","family":"Keesler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica H.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12064_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0015","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von willebrand disease: a report of the subcommittee on von willebrand factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pcl.2008.01.008","article-title":"Von Willebrand disease","volume":"55","author":"Robertson","year":"2008","journal-title":"Pediatr Clin North Am"},{"key":"10.1002\/rth2.12064_bb0025","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0030","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM\u20101VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jth.12130","article-title":"The genetics of canadian type 3 von Willebrand disease: further evidence for co\u2010dominant inheritance of mutant alleles","volume":"11","author":"Bowman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"Von Willebrand disease (VWD): evidence\u2010based diagnosis and management guidelines, the national heart, lung, and blood institute (NHLBI) expert panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12064_bb0045","doi-asserted-by":"crossref","first-page":"23352","DOI":"10.1074\/jbc.270.40.23352","article-title":"Characterization of the unique mechanism mediating the shear\u2010dependent binding of soluble von Willebrand factor to platelets","volume":"270","author":"Goto","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1002\/rth2.12064_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2010.03.003","article-title":"The genetic basis of von Willebrand disease","volume":"24","author":"Goodeve","year":"2010","journal-title":"Blood Rev"},{"key":"10.1002\/rth2.12064_bb0055","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2011-10-384610","article-title":"VWF mutations and new sequence variations identified in healthy controls are more frequent in the african\u2010american population","volume":"119","author":"Bellissimo","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0021-9258(17)42483-5","article-title":"Von Willebrand factor. A reduced and alkylated 52\/48\u2010kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein ib","volume":"261","author":"Fujimura","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1002\/rth2.12064_bb0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJM198005083021902","article-title":"Heightened interaction between platelets and factor VIII\/von Willebrand factor in a new subtype of von Willebrand's disease","volume":"302","author":"Ruggeri","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12064_bb0070","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2008-04-152280","article-title":"Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients","volume":"113","author":"Federici","year":"2009","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.bpj.2014.07.026","article-title":"Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease","volume":"107","author":"Tischer","year":"2014","journal-title":"Biophys J"},{"key":"10.1002\/rth2.12064_bb0080","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0037-1616142","article-title":"Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen","volume":"86","author":"Ribba","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0085","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2008-10-184317","article-title":"Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von willebrand factor","volume":"114","author":"Riddell","year":"2009","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0090","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/j.1538-7836.2010.03869.x","article-title":"Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD","volume":"8","author":"Flood","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0095","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/pbc.23120","article-title":"Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease","volume":"57","author":"Gupta","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/rth2.12064_bb0105","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hae.12503","article-title":"Normal range of bleeding scores for the ISTH\u2010BAT: adult and pediatric data from the merging project","volume":"20","author":"Elbatarny","year":"2014","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12064_bb0115","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2004.00933.x","article-title":"Slippery criteria for von Willebrand disease type 1","volume":"2","author":"Sadler","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0120","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a united kingdom haemophilia centre doctors organization guideline approved by the british committee for standards in haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12064_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM\u20101VWD)","volume":"109","author":"Goodeve","year":"2007","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0140","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0145","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C\u2010type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"Rydz","year":"2013","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0150","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/jth.12927","article-title":"CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease","volume":"13","author":"Sanders","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0155","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1055\/s-0034-1389079","article-title":"Von Willebrand factor and aging","volume":"40","author":"Konkle","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12064_bb0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2009.11.003","article-title":"Factor V leiden and hemophilia","volume":"125","author":"Franchini","year":"2010","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12064_bb0165","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"Von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"Sadler","year":"2003","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.V41.5.687.687","article-title":"Ristocetin: a means of differentiating von Willebrand's disease into two groups","volume":"41","author":"Howard","year":"1973","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0175","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-2006-947863","article-title":"Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom national external quality assessment scheme for blood coagulation","volume":"32","author":"Kitchen","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12064_bb0180","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-2006-947862","article-title":"An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the european concerted action on thrombosis and disabilities foundation","volume":"32","author":"Meijer","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12064_bb0185","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1309\/CEPND3LFHQ87XU4D","article-title":"A new automated screening assay for the diagnosis of von Willebrand disease","volume":"127","author":"Salem","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1002\/rth2.12064_bb0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0037-1613765","article-title":"A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor","volume":"83","author":"Vanhoorelbeke","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0195","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1002\/rth2.12064_bb0200","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet\u2010dependent von willebrand factor activity. nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bodo","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0205","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-2007-1000364","article-title":"An update on the von Willebrand factor collagen binding assay: 21\u00a0years of age and beyond adolescence but not yet a mature adult","volume":"33","author":"Favaloro","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12064_bb0210","doi-asserted-by":"crossref","first-page":"13835","DOI":"10.1016\/S0021-9258(19)76501-6","article-title":"Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III","volume":"262","author":"Pareti","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1002\/rth2.12064_bb0215","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/j.1365-2516.2011.02676.x","article-title":"A family with type 2M VWD with normal VWF:RCo but reduced VWF:CB and a M1761K mutation in the A3 domain","volume":"18","author":"Keeling","year":"2012","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12064_bb0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI115285","article-title":"150\u2010kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen","volume":"88","author":"Rand","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1002\/rth2.12064_bb0225","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1538-7836.2012.04746.x","article-title":"Critical von Willebrand factor A1 domain residues influence type VI collagen binding","volume":"10","author":"Flood","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0038-1651577","volume":"69","author":"Sadler","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0235","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/jth.13742","article-title":"Clinical and laboratory phenotype variability in type 2M von Willebrand disease","volume":"15","author":"Doruelo","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0240","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0245","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM\u20101VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood"},{"key":"10.1002\/rth2.12064_bb0250","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.thromres.2014.12.017","article-title":"Clinical use of haemate(R) P in von Willebrand disease: a 25\u2010year retrospective observational study","volume":"135","author":"Miesbach","year":"2015","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12064_bb0255","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH10-10-0631","article-title":"Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (wilate(R)) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery","volume":"105","author":"Windyga","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0260","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high\u2010purity von Willebrand factor concentrate (wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel\u2010Derlon","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12064_bb0265","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922016430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922016430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/rth2.12064\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:16:53Z","timestamp":1762863413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922016430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2475037922016430"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12064","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current issues in diagnosis and treatment of von Willebrand disease","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}